Review on niosomalstructure Through nasal Route

Show simple item record

dc.contributor.author Abd Elaty Mostafa, Dalia
dc.contributor.author Mostafa Hashad, Amira
dc.date.accessioned 2020-02-29T08:46:09Z
dc.date.available 2020-02-29T08:46:09Z
dc.date.issued 2018
dc.identifier.citation [1] AG seleci,d.,seleci,m.,walter,j. g.,stahl,f.&scheper,T.2016.NiosomesasNanoparticularDrugCarriers:FundamentalsandRecentA pplications.Journal of Nanomaterials,2016. [2] Aggarwal,r.,cardozo,a.&homer,J.2004.Theassessmentoftopicalnasal drug distribution.Clinical Otolaryngology,29, 201-205. [3] AlyautdinR,KhalinI,NafeezaMI,HaronMH,KuznetsovD.Nanoscaledrugdeliverysystemsandtheblood– brainbarrier.IntJNanomedicine.2014;9:795–811 [4] Appasaheb,p.s.,manohar,s.d.,bhanudas,s.r.&anjaneri,N.2013.Areviewonintranasaldrugdeliverysystem.JournalofAdvancedPharmac y Education&Research Oct-Dec, 3. [5] Arora,p.,sharma,s.&garg,S.2002.Permeabilityissuesinnasaldrugdelivery.Drug discovery today, 7, 967-975. [6] Bagheri,A.,Chu,B.S.andYaakob,H.,2014.Niosomaldrugdeliverysystems:formulation,preparationandapplications.WorldApplSciJ, 32(8),pp.1671-1685. [7] Bakke,h.,samdal,h.,holst,j.,oftung,f.,haugen,i.,kristoffersen,a.c.,haugan,a.,janakova,l.,korsvold,g.&krogh,G.2006Oralsprayimmu nizationmaybeanalternativetointranasalvaccinedeliverytoinducesystemicantibodiesbutnotnasalmucosalorcellularimmunity.Scandi navianjournalofimmunology,63,223-231 [8] Bini,k.,akhilesh,d.,prabhakara,p.&jv,k.2012.Developmentandc h a r a c t e r i z a t i o n ofnonionicsurfactantvesicles(niosomes) fo oraldeliveryoflornoxicam.InternationalJournalofDrugDevelopmentandResearch. [9] Bitter,c.,suter-zimmermann,k.&surber,C.2011.Nasaldrugdeliveryin humans.Topical Applications and the Mucosa.Karger Publishers. [10] Chandu, V.P., Arunachalam, A., Jeganath, S., Yamini, K., Tharangini, K. and Chaitanya, G., 2012. Niosomes: a novel drug delivery system. Int J Novel Trends Pharm Sci, 2(1), pp.25-31. [11] Das,K.andRam,A.,2013.Niosomeasanoveldrugdeliverysystemareview.International Journal AppliedPharmacy,1(6), pp.1-7. [12] Djupesland,P.G.2013.Nasaldrugdeliverydevices:characteristicsandperformanceinaclinicalperspective— areview.Drugdeliveryandtranslational research,3, 42-62. [13] Djupesland,p.g.&skretting,A.2012.Nasaldepositionandclearanceinman:comparisonofabidirectionalpowderdeviceandatraditionalli quidspraypump.Journalofaerosolmedicineandpulmonarydrug delivery,25, 280-289. [14] Djupesland,p.g.,skretting,a.,winderen,m.&holand,T.2004.Bidirectionalnasaldeliveryofaerosolscanpreventlungdeposition.Journal of aerosol medicine, 17, 249-259. [15] Fonseca-Santos, B., Gremião, M.P.D. and Chorilli, M., 2015. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. International journal of nanomedicine, 10, p.4981. [16] Gadhiya, P., Shukla, S., Modi, D. and Bharadia, P., 2012. A Review- Niosomes in Targeted Drug Delivery. International Journal for Pharmaceutical Research Scholars, 2, p.61. [17] Gupta,A.,Arora,A.,Menakshi,A.,Sehgal,A.andSehgal,R.,2012.Nanotechnologyand its applications in drugdelivery: areview. [18] Guterres,S.S.,Alves,M.P.andPohlmann,A.R.,2007.Polymericnanoparticles,nanospheres andnanocapsules,for cutaneousapplications.Drugtarget insights, 2, p.147. [19] Hu,C.andRhodes,D.G.,2000.Erratumto‘Proniosomes:ANovelDrugCarrierPreparation’:[Int.J.Pharm.185(1999)23– 35].Internationaljournalofpharmaceutics,206(1), pp.109-122. [20] Kaur,i.p.,bhandari,r.,bhandari,s.&kakkar,V.2008.Potentialofsolidlipidnanoparticlesinbraintargeting.JournalofControlledRelease,1 27, 97-109. [21] Kaur,I.P.,Garg,A.,Singla,A.K.andAggarwal,D.,2004.Vesicularsystemsinoculardrugdelivery:anoverview.Internationaljournalofph armaceutics,269(1),pp.1- [22] Kumar,G.P.andRajeshwarrao,P.,2011.Nonionicsurfactantvesicularsystemsforeffectivedrugdelivery anoverview.ActaPharmaceuti caSinicaB, 1(4),pp.208-219. [23] Mahale, n., thakkar, p., mali, r., walunj, d. &chaudhari, s. 2012. Niosomes: novel sustained release nonionic stable vesicular systems— an overview. Advances in colloid and interface science, 183, 46-54. [24] Mainardes, R.M. and Gremião, M.P.D., 2012. Nanoencapsulation and Characterization of Zidovudine on Poly (L-lactide) and Poly (L-lactide)—Poly (ethylene glycol)-Blend Nanoparticles. Journal of nanoscience and nanotechnology, 12(11), pp.8513-[25] Majgainya, s., soni, s. &bhat, p. novel approach for nose- to-brain drug delivery bypassing blood brain barrier by pressurized olfactory delivery device. [26] Makeshwar, K.B. and Wasankar, S.R., 2013. Niosome: a Novel Drug Delivery System. Asian journal of pharmaceutical research, 3(1), pp.16-20. [27] Management, C. W. O. G. F. A. S. D. 2008. Guideline for Alzheimer's disease management: final report, State of California, Department of Public Health. [28] Manda, R., Suthakaran, R., Kaya, V., Sreedevi, B. and Hurumathfathima, T., 2014. NIOSOME: AN UNIQUE DRUG DELIVERY SYSTEM. [29] McClements, D.J., 2012. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft matter, 8(6), pp.1719-1729. [30] Mehnert, W. and Mäder, K., 2001. Solid lipid nanoparticles: production, characterization and applications. Advanced drug delivery reviews, 47(2), pp.165-196. [31] MOHANRAJ, V. & CHEN, Y. 2006. Nanoparticles-a review. Tropical Journal of Pharmaceutical Research, 5, 561-573. [32] Odeh,F.,AlJaber,H.andKhater,D.,2014.Nanoflorahownanotechnologyenhancedtheuseofactivephytochemicals.ApplicationofNan otechnologyinDrugDelivery, pp.1-15. [33] Pardridge,W.M.2007.Drugtargetingtothebrain.Pharmaceuticalresearch, 24, 1733-1744. [34] Seleci, m., agseleci, d., joncyzk, r., stahl, f., blume, c. &scheper, T. 2016. Smart multifunctional nanoparticles in nanomedicine. BioNanoMaterials, 17, 33-41. [35] Singh, p., prakash, d., ramesh, b., singh, n. &mani, T. T. 2011. Biodegradable polymeric microspheres as drug carriers; A review. Ind J Nov Drug Del, 3, 70-82. [36] Tangri, P. and Khurana, S., 2011. Niosomes: formulation and evaluation. International Journal, 2229, p.7499. [37] Tavano, l., gentile, l., rossi, c. o. &muzzalupo, r. 2013. Novel gel-niosomes formulations as multicomponent systems for transdermal drug delivery. Colloids and Surfaces B: Biointerfaces, 110, 281-288. [38] Tegeli, v., thorat, y., chougule, g., shivsharan, u., gajeli,g. &kumbhar, S. 2010. Review on concepts and advances in prodrug technology. International Journal of Drug Formulation & Research, 1, 32-57. [39] Tyagi, S., 2012. Novel Drug Delivery System (NDDS): Niosomes. Journal of Biomedical and Pharmaceutical Research, 1(03). [40] Verma, p., thakur, a., deshmukh, k., jha, a. &verma, S. 2010. Routes of drug administration. International Journal of Pharmaceutical Studies and Research, 1, 54-59. [41] Verma, r. k. &garg, s. 2001. Drug delivery technologies and future directions. Pharmaceutical Technology, 25, 1-14. en_US
dc.identifier.issn e-ISSN:2278-3008
dc.identifier.issn p-ISSN:2319-7676
dc.identifier.other https://doi.org/
dc.identifier.uri https://t.ly/R0qlZ
dc.description MSA Google Scholar en_US
dc.description.abstract Nanotechnology has created one of the most dynamic science and technology domains at the confluence of physical sciences, molecular engineering, biology, biotechnology and medicine. There has been a considerable research interest in the area of developing drug delivery using nanoparticles (NP’s) as carriers for small and large molecules. Targeting delivery of drugs to the diseased lesions is one of the most important aspects of drug delivery system especially brain. They have been used in-vivo to protect the drug entity in the systemic circulation, restrict access of the drug to the chosen sites and to deliver the drug at a controlled and sustained rate to this site of action. Niosomes are non-ionic surfactant vesicles obtained on hydration of synthetic nonionic surfactants, with or without incorporation of cholesterol or other lipids. They are vesicular systems similar to liposomes that can be used as carriers of amphiphilic and lipophilic drugs. Various polymers have been used in the formulation of niosomes for drug delivery research to increase therapeutic benefit, while minimizing the side-effects. It is obvious that niosome appears to be a well preferred drug delivery system over liposome as niosome being stable and economic. Also niosomes have great drug delivery potential for targeted delivery of anti-cancer, antiinfective agents.Drug delivery potential of niosome can enhance by using novel concepts like proniosomes, discomes and aspasome.Niosomes represent a promising drug delivery module. Niosomes are thoughts to be better candidates drug delivery as compared to liposomes due to various factors like cost, stability etc. Various types of drug deliveries can be possible using niosomes like targeting, ophthalmic, topical and parenteral. en_US
dc.language.iso en en_US
dc.publisher Journal of Pharmacy and Biological Sciences en_US
dc.relation.ispartofseries IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS);Volume 13, Issue 1 Ver. V (Jan. – Feb. 2018), PP 29-40
dc.subject Nanotechnology en_US
dc.subject niosomes en_US
dc.subject nasal route en_US
dc.subject targeting en_US
dc.title Review on niosomalstructure Through nasal Route en_US
dc.type Article en_US
dc.identifier.doi https://doi.org/
dc.Affiliation October University for modern sciences and Arts (MSA)


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MSAR


Advanced Search

Browse

My Account